VEGFA rs3025039 is associated with phenotype severity of myelofibrosis‐type megakaryocyte dysplasia
Giovanni Barosi,
Paolo Catarsi,
Rita Campanelli,
Margherita Massa,
Adriana Carolei,
Carlotta Abbà,
Annalisa deSilvestri,
Robert Peter Gale,
Vittorio Rosti
Affiliations
Giovanni Barosi
Center for the Study of Myelofibrosis General Medicine 2 Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation Pavia Italy
Paolo Catarsi
Center for the Study of Myelofibrosis General Medicine 2 Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation Pavia Italy
Rita Campanelli
Center for the Study of Myelofibrosis General Medicine 2 Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation Pavia Italy
Margherita Massa
Center for Systemic Amyloidoses and High Complexity Diseases General Medicine 2 Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation Pavia Italy
Adriana Carolei
Center for the Study of Myelofibrosis General Medicine 2 Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation Pavia Italy
Carlotta Abbà
Center for Systemic Amyloidoses and High Complexity Diseases General Medicine 2 Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation Pavia Italy
Annalisa deSilvestri
Biometry and Clinical Epidemiology Scientific Direction Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation Pavia Italy
Robert Peter Gale
Department of Immunology and Inflammation Centre for Haematology Research Imperial College London London UK
Vittorio Rosti
Center for the Study of Myelofibrosis General Medicine 2 Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation Pavia Italy
